STOCK TITAN

MediWound Ltd - MDWD STOCK NEWS

Welcome to our dedicated news page for MediWound (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on MediWound.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MediWound's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MediWound's position in the market.

Rhea-AI Summary
MediWound Ltd. has announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx® in venous leg ulcers (VLUs). Mölnlycke will provide its Mepilex® Up dressing along with other dressings for the study. The study aims to evaluate the efficacy and safety of EscharEx in the debridement of chronic wounds, with a focus on VLUs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
-
Rhea-AI Summary
MediWound Ltd. has entered into a research collaboration agreement with MIMEDX Group, Inc. for a Phase III study in venous leg ulcers (VLUs). MIMEDX will provide its placental tissue allograft EPIFIX® for the wound healing phase of the study. The goal is to maintain consistency and optimize healing potential. EscharEx, the product being evaluated, aims to debride chronic wounds in VLUs. This study is expected to provide valuable insights to the wound care industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
MediWound Ltd

Nasdaq:MDWD

MDWD Rankings

MDWD Stock Data

151.77M
5.02M
25.73%
33.91%
1.71%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Israel
42 Hayarkon Street

About MDWD

mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and